Kenvue (KVUE) Set to Announce Earnings on Tuesday

Kenvue (NYSE:KVUE) will be releasing its earnings data before the market opens on Tuesday, August 6th. Analysts expect Kenvue to post earnings of $0.29 per share for the quarter. Kenvue has set its FY24 guidance at $1.10-$1.20 EPS.Parties interested in listening to the company’s conference call can do so using this link.

Kenvue (NYSE:KVUE) last announced its earnings results on Tuesday, May 7th. The company reported $0.28 earnings per share for the quarter, beating the consensus estimate of $0.25 by $0.03. The company had revenue of $2.89 billion during the quarter, compared to the consensus estimate of $3.79 billion. Kenvue had a return on equity of 21.06% and a net margin of 9.63%. The firm’s quarterly revenue was down 24.9% compared to the same quarter last year. On average, analysts expect Kenvue to post $1 EPS for the current fiscal year and $1 EPS for the next fiscal year.

Kenvue Stock Up 1.0 %

Shares of Kenvue stock opened at $18.82 on Monday. The company has a market capitalization of $36.04 billion, a PE ratio of 24.13, a P/E/G ratio of 2.07 and a beta of 1.38. Kenvue has a 1-year low of $17.67 and a 1-year high of $24.43. The business has a 50-day moving average of $18.49 and a 200-day moving average of $19.43. The company has a debt-to-equity ratio of 0.66, a current ratio of 0.99 and a quick ratio of 0.68.

Kenvue Increases Dividend

The company also recently declared a quarterly dividend, which will be paid on Wednesday, August 28th. Investors of record on Wednesday, August 14th will be paid a $0.205 dividend. This represents a $0.82 dividend on an annualized basis and a yield of 4.36%. This is an increase from Kenvue’s previous quarterly dividend of $0.20. The ex-dividend date of this dividend is Wednesday, August 14th. Kenvue’s dividend payout ratio (DPR) is 102.56%.

Wall Street Analysts Forecast Growth

A number of equities research analysts have recently weighed in on the company. HSBC lifted their price target on Kenvue from $20.00 to $21.00 and gave the company a “hold” rating in a report on Wednesday, May 8th. Citigroup cut their price target on Kenvue from $21.00 to $20.00 and set a “neutral” rating on the stock in a report on Wednesday, July 10th. Sanford C. Bernstein assumed coverage on Kenvue in a report on Thursday, April 11th. They set an “underperform” rating and a $18.00 price target on the stock. Deutsche Bank Aktiengesellschaft cut their price target on Kenvue from $24.00 to $23.00 and set a “buy” rating on the stock in a report on Thursday, July 25th. Finally, JPMorgan Chase & Co. dropped their target price on Kenvue from $23.00 to $22.00 and set an “overweight” rating on the stock in a report on Monday, July 22nd. One equities research analyst has rated the stock with a sell rating, seven have assigned a hold rating and five have assigned a buy rating to the stock. According to data from MarketBeat.com, the company presently has a consensus rating of “Hold” and a consensus target price of $22.45.

Kenvue Company Profile

Kenvue Inc operates as a consumer health company worldwide. The company operates through three segments: Self Care, Skin Health and Beauty, and Essential Health. The Self Care segment offers cough, cold and allergy, pain care, digestive health, smoking cessation, eye care, and other products under the Tylenol, Motrin, Benadryl, Nicorette, Zarbee's, ORSLTM, Rhinocort, Calpol, and Zyrtec brands.